Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad125 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, 2023. Verfasst von Ajoy Oommen John und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Christian Medical College, Vellore, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Veterans Affairs Ann Arbor Lung Precision Oncology Program.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) remains a major cause of morbidity and mortality worldwide. One-third of NSCLC patients present with surgically resectable, non-metastatic disease; however, many of these patients will recur despite curative surgery and adjuvant therapy. The recent publication of randomized trials incorporating immune check-point inhibitors (ICI) to the standard neo-adjuvant and adjuvant treatment regimens has reported improved survival with manageable toxicity profiles. The IMpower 010 studied the use of adjuvant atezolizumab after standard surgery and adjuvant chemotherapy. They demonstrated an improvement in 3-year disease-free survival (DFS) prompting a change in treatment guidelines. The Checkmate 816 and NADIM II studies evaluated the addition of pembrolizumab and nivolumab, respectively, to standard neo-adjuvant chemotherapy. The results from both trials showed an improvement in 2-year event-free survival (EFS) and 2-year PFS (PFS), respectively. In this review, we summarize the prior data regarding adjuvant and neo-adjuvant chemotherapy in NSCLC and elaborate on results from the newer trials incorporating ICIs. We briefly discuss the pros and cons of each treatment approach along with areas that need further clarity to inform clinical practice and future directions for research in this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Christian Medical College, Vellore, India.
- Division of Medical Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
- Department of Medicine, Section of Medical Oncology, Veterans Administration, Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Förderung
- Veterans Affairs Ann Arbor Lung Precision Oncology Program
Zitieren
APA
John, A. O., & Ramnath, N. (2023). Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy. The Oncologist. https://doi.org/10.1093/oncolo/oyad125
Vancouver
John AO, Ramnath N. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy. The Oncologist. 2023. doi:10.1093/oncolo/oyad125
BibTeX
@article{John2023,
author = {John, Ajoy Oommen and Ramnath, Nithya},
title = {Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad125}
}
EUVIMED